c-kit is involved in hematopoietic stem cell self-renewal, however it is also found in other stem cells as well. For example, cardiac stem cells express c-kit. This is an exciting drug target and other companies have patents covering its inhibitors, for example, #7,211,600 by Sugen.
The current patent covers composition of matter for various chemical entities that are capable of modulatin c-kit activity.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.